Generate and Novartis enter $1B Collaboration to Develop AI-driven Protein Therapeutics

Somerville, MA, September 24, 2024 (Business Wire) -- Generate:Biomedicines (“Generate”) has entered a multi-target collaboration with Novartis to develop protein therapeutics using its generative AI platform. The deal includes a $65 million upfront payment, with the potential for over $1 billion in milestone payments, as the companies aim to create first-in-class treatments across multiple disease areas. The collaboration merges cutting-edge AI with Novartis’s deep expertise to accelerate drug discovery and bring new medicines to market faster.

Read full article here.